{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=8", "query": { "condition": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1726, "total_pages": 173, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Precursor+Cell+Lymphoblastic+Leukemia-Lymphoma&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:19:36.743Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00290706", "title": "A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2006-04-07", "completion_date": "2012-09-05", "has_results": true, "last_update_posted_date": "2019-05-28", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 3, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290706" }, { "nct_id": "NCT01217996", "title": "Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Tumor", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Computerized working memory training program (intervention)", "type": "BEHAVIORAL" }, { "name": "Computerized working memory training program (control)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 128, "start_date": "2010-10", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217996" }, { "nct_id": "NCT04996160", "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric", "Relapsed Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanja Andrea Gruber", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 2, "start_date": "2021-07-09", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996160" }, { "nct_id": "NCT04013685", "title": "Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoid Leukemia", "Myelodysplastic Syndromes", "Acute Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Orca-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Orca Biosystems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 155, "start_date": "2019-11-21", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 21, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013685" }, { "nct_id": "NCT00005985", "title": "Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 213, "start_date": "2000-08", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005985" }, { "nct_id": "NCT04666025", "title": "SARS-CoV-2 Donor-Recipient Immunity Transfer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Accelerated Phase CML, BCR-ABL1 Positive", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Phase CML, BCR-ABL1 Positive", "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Hodgkin Lymphoma", "Lymphoblastic Lymphoma", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-09-23", "completion_date": "2023-05-05", "has_results": false, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666025" }, { "nct_id": "NCT00324324", "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "moxifloxacin hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 240, "start_date": "2006-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324324" }, { "nct_id": "NCT00024180", "title": "FR901228 in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-01", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024180" }, { "nct_id": "NCT04629430", "title": "Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Non Hodgkin Lymphoma", "Acute Lymphocytic Leukemia", "Hodgkin Lymphoma", "Hodgkin Disease", "Myelofibrosis", "Myelodysplastic Syndromes", "Myeloproliferative Neoplasm", "Sickle Cell Disease", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Pre-biotic foods/drinks", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-02-19", "completion_date": "2022-10-28", "has_results": false, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629430" }, { "nct_id": "NCT05694364", "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Acute Lymphoblastic Leukemia", "Diffuse Large B Cell Lymphoma", "Triple Negative Breast Cancer Malignancies" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "PRGN-3007", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-01-25", "completion_date": "2024-04-18", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-11-15T10:19:36.743Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05694364" } ] }